<DOC>
	<DOCNO>NCT00597402</DOCNO>
	<brief_summary>Primary objective : To use overall survival ass efficacy combination radiation therapy , temozolomide Avastin follow Avastin , temozolomide , irinotecan treatment grade IV malignant glioma patient follow surgical resection . Secondary objective : To determine progression-free survival follow combination radiation therapy , temozolomide Avastin follow Avastin , temozolomide , irinotecan . Exploratory Objective : To explore relationship biomarkers outcome ( overall survival progression-free survival ) among patient grade IV malignant glioma treat radiation therapy , temozolomide Avastin follow Avastin , temozolomide , irinotecan . To describe toxicity radiation therapy , temozolomide Avastin follow Avastin , temozolomide , irinotecan .</brief_summary>
	<brief_title>Avastin Combination With Radiation ( XRT ) &amp; Temozolomide , Followed Avastin , Temozolomide Irinotecan Glioblastoma ( GBM ) Gliosarcomas</brief_title>
	<detailed_description>The standard care grade IV glioma radiation therapy daily temozolomide , follow 6 month temozolomide . The majority patient progress die tumor . Many glioma patient resistant temozolomide tumor high O ( 6 ) -methylguanine-DNA methyltransferase ( MGMT ) , confer resistance . Irinotecan synergistic temozolomide , combination may overcome high MGMT . Vascular endothelial growth factor ( VEGF ) present cell surface around malignant glioma . It appear presence vascular endothelial growth factor prognostic growth factor VEGF expression correlate poor prognosis . Monoclonal antibody VEGF inhibit growth malignant glioma mouse xenograft . Avastin humanize monoclonal immunoglobulin G ( IGG ) 1 antibody bind inhibits biologic activity human vascular endothelial growth factor . The combination Avastin irinotecan safe demonstrate high activity recurrent malignant glioma . The combination Avastin , temozolomide , irinotecan initial therapy may maximize chance long-term survival . There study complete ongoing newly diagnose glioblastoma ( GBM ) patient , include Radiation Therapy Oncology Group ( RTOG ) study add irinotecan temozolomide follow standard radiation therapy temozolomide , University California , Los Angeles ( UCLA ) study add Avastin standard radiation therapy temozolomide follow Avastin temozolomide .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Patients must histologically confirm diagnosis World Health Organization ( WHO ) grade IV primary malignant glioma ( glioblastoma multiforme gliosarcoma ) . Patients within 4 week last major surgical procedure . Age &gt; 18 year . An interval least 2 week &gt; 6 week prior major surgical procedure study enrollment . No prior radiotherapy chemotherapy brain tumor Karnofsky ≥ 60 percent . Hemoglobin ≥ 9.0 g/deciliter ( dl ) , absolute neutrophil count ( ANC ) ≥ 1,500 cells/ microliter , platelet ≥ 125,000 cells/microliter . Serum creatinine ≤ 1.5 mg/dl , serum serum glutamicoxaloacetic transaminase ( SGOT ) bilirubin ≤ 1.5 time upper limit normal ( ULN ) . For patient corticosteroid , must stable decrease dose 1 week prior entry , dose escalated entry dose level , clinically possible . Signed informed consent approve Institutional Review Board No evidence &gt; grade 1 central nervous system ( CNS ) hemorrhage baseline MRI CT scan . If sexually active , patient take contraceptive measure duration treatment state informed consent . Pregnancy breast feed . Comedication may interfere study result ; e.g . immunosuppressive agent corticosteroid . Active infection require intravenous ( IV ) antibiotic . Prior treatment radiotherapy chemotherapy brain tumor , irrespective grade tumor . Evidence &gt; grade 1 CNS hemorrhage baseline MRI CT scan . AvastinSpecific Concerns : Subjects meet follow criterion ineligible study entry : Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study Blood pressure 150/100 mmHg Unstable angina New York Heart Association ( NYHA ) Grade II great congestive heart failure History myocardial infarction within 6 month History stroke within 6 month Clinically significant peripheral vascular disease Evidence bleed diathesis Coagulopathy ( prothrombin time ( PT ) partial thromboplastin time ( PTT ) &gt; 1.5x normal history &gt; three grade 2 great hemorrhage ) Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior first Avastin infusion XRT/Temodar anticipation need major surgical procedure course study Minor surgical procedure , fine needle aspiration core biopsy within 7 day prior first Avastin infusion XRT/Temodar Pregnant ( positive pregnancy test ) lactate Urine protein &gt; 1.0 + screen History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior first Avastin infusion XRT/Temodar Serious , nonhealing wound , ulcer , bone fracture . Inability comply study and/or followup procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Avastin</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>Temodar</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>Camptosar</keyword>
	<keyword>GBM</keyword>
	<keyword>Glioblastoma Multiforme</keyword>
	<keyword>Gliosarcoma</keyword>
	<keyword>Brain tumor</keyword>
	<keyword>Glioma</keyword>
	<keyword>New GBM</keyword>
	<keyword>Newly diagnose GBM gliosarcoma malignant brain tumor</keyword>
</DOC>